Sequana Medical NV Total Liabilities

Latest as of June 2025: €53.74 Million EUR ≈ $62.83 Million USD

Sequana Medical NV total liabilities. Based on the latest financial reports, Sequana Medical NV (SEQUA) has total liabilities worth €53.74 Million EUR (≈ $62.83 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Sequana Medical NV defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Total Liabilities of Sequana Medical NV (2014–2024)

Total liabilities of Sequana Medical NV from 2014 to 2024. This chart illustrates how Sequana Medical NV's total liabilities have evolved over time, based on quarterly financial data.

Sequana Medical NV Competitors by Total Liabilities

The table below lists competitors of Sequana Medical NV ranked by their total liabilities.

Company Country Total Liabilities
Manomay Tex India Limited
NSE:MANOMAY
India Rs5.05 Billion
Clene Inc.
NASDAQ:CLNN
USA $47.82 Million
Ene Technology Inc
TW:6243
Taiwan NT$393.92 Million
NexMetals Mining Corp. Common Shares
NASDAQ:NEXM
USA $15.56 Million
Helium Evolution Inc
V:HEVI
Canada CA$1.39 Million
Inter Industries
TA:ININ
Israel ILA348.93 Million
Etherstack Plc
AU:ESK
Australia AU$12.36 Million
One and One Green Technologies. Inc Class A Ordinary Shares
NASDAQ:YDDL
USA $14.22 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Sequana Medical NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sequana Medical NV (SEQUA) total assets.

Liquidity & Leverage Metrics

Sequana Medical NV Total Liabilities Ratios Explained

Sequana Medical NV total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.20 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.37 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 3.69 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sequana Medical NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sequana Medical NV (2014–2024)

The table below shows the annual total liabilities of Sequana Medical NV from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 €54.32 Million
≈ $63.51 Million
+83.73%
2023-12-31 €29.57 Million
≈ $34.57 Million
+4.92%
2022-12-31 €28.18 Million
≈ $32.94 Million
+81.89%
2021-12-31 €15.49 Million
≈ $18.11 Million
+9.87%
2020-12-31 €14.10 Million
≈ $16.49 Million
+67.38%
2019-12-31 €8.42 Million
≈ $9.85 Million
-61.88%
2018-12-31 €22.10 Million
≈ $25.84 Million
+171.85%
2017-12-31 €8.13 Million
≈ $9.50 Million
-22.39%
2016-12-31 €10.48 Million
≈ $12.25 Million
+110.92%
2015-12-31 €4.97 Million
≈ $5.81 Million
+55.52%
2014-12-31 €3.19 Million
≈ $3.73 Million
--

About Sequana Medical NV

BR:SEQUA Belgium Medical Devices
Market Cap
$55.84 Million
€47.76 Million EUR
Market Cap Rank
#21880 Global
#91 in Belgium
Share Price
€0.61
Change (1 day)
+0.00%
52-Week Range
€0.47 - €0.76
All Time High
€11.80
About

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid over… Read more